Document Detail

Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C.
MedLine Citation:
PMID:  23043382     Owner:  NLM     Status:  In-Data-Review    
Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease with an estimated 170 million carriers worldwide. Current treatments have significant side effects and have met with only partial success. Therefore, alternative antiviral drugs that efficiently block virus production are needed. During recent decades, RNA interference (RNAi) technology has not only become a powerful tool for functional genomics but also represents a new therapeutic approach for treating human diseases including viral infections. RNAi is a sequence-specific and post-transcriptional gene silencing process mediated by double-stranded RNA (dsRNA). As the HCV genome is a single-stranded RNA that functions as both a messenger RNA (mRNA) and replication template, it is an attractive target for the study of RNAi-based viral therapies. In this review, we will give a brief overview about the history and current status of RNAi and focus on its potential application as a therapeutic option for treatment for HCV infection.
M Motavaf; S Safari; S M Alavian
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  19     ISSN:  1365-2893     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  England    
Other Details:
Languages:  eng     Pagination:  757-65     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Tehran Hepatitis Center (THC), Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Testing the activitystat hypothesis: a randomised controlled trial protocol.
Next Document:  Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receivin...